Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × pCR Rate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10079 Neoplasms 7745 Carcinoma, Non-Small-Cell Lung 5696 Prostatic Neoplasms 4967 Colorectal Neoplasms 4541 Lung Neoplasms 3681 Leukemia, Myeloid, Acute 3067 Neoplasm Metastasis 3057 Multiple Myeloma 3051 Pancreatic Neoplasms 2812 Melanoma 2634 Lymphoma 2561 Ovarian Neoplasms 2548 Carcinoma, Hepatocellular 2450 Stomach Neoplasms 2302 Recurrence 2206 Head and Neck Neoplasms 2078 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2074 Lymphoma, Non-Hodgkin 2049 Leukemia 2006 Brain Neoplasms 1887 Colonic Neoplasms 1781 Glioblastoma 1776 Leukemia, Lymphocytic, Chronic, B-Cell 1766 Rectal Neoplasms 1703 Uterine Cervical Neoplasms 1668 Lymphoma, Follicular 1635 Squamous Cell Carcinoma of Head and Neck 1631 Lymphoma, Large B-Cell, Diffuse 1590 Carcinoma, Renal Cell 1559

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡